·Zhejiang Dongyang Base started construction with a total investment of not less than 5 billion
·Low-carbon high-end battery aluminum foil project started construction in Yichang, Hubei
·HEC Pharmaceutical Research Institute completed A round of financing of nearly 7 billion yuan
·HEC Pharmaceutical Research Institute completed the equity control of HEC Pharmaceutical (01558.HK), realizing the integration of pharmaceutical assets
·Mr. Zhang Yushuai took over as chairman of HEC Group and established a new board of directors of HEC Group. HEC officially entered the 2.0 new era of "co-creation, co-responsibility and sharing"
·HEC's first Class 1.1 original innovative drug "Emitasvir Phosphate" was approved for marketing
·Cordyceps sinensis (breeding product) was included in "Guangdong Province Local Medicinal Materials Standard" (Volume 3)
·"Research on key technologies of Cordyceps sinensis breeding and its industrial application" won the first prize of Guangdong Science and Technology Progress Award
·HEC Pharma was listed on the main board of Hong Kong, stock code: 01558.HK
·HEC Pharmaceutical Research Institute is approved by the Ministry of Science and Technology of the People's Republic of China to establish a "State Key Laboratory of New Anti-infective Drug Research and Development"
Zunyi Base in Guizhou started construction
·HEC A-share backdoor listing, stock code: 600673.SH
·Dongguan Songshan Lake Factory started construction
·Guangdong Dongguan Base started construction
·Acquired Hubei Changhe Pharmaceutical Co., Ltd. and officially entered the pharmaceutical industry